| Full Company Name | IX BIOPHARMA LTD. |
|---|---|
| Incorporated In | SINGAPORE |
| Incorporated On | 20040508 |
| ISIN Code | SG1BD9000009 |
| Listing | Listed on 22 July 2015 on Catalist |
| Listing Board | CATALIST |
| Trading Currency | SGD |
| Website | http://www.ixbiopharma.com |
| Telephone | 65 62352270 |
| Fax | 65 62352170 |
| Registered Office |
20 Collyer Quay #11-07 Singapore 049319 |
| Secretary |
Lai Kuan Loong Victor Lee Soo Fern Gwendolin |
| Registrar / Transfer Agent | TRICOR BARBINDER SHARE REGISTRATION SERVICES |
| Registrar Address | 9 Raffles Place, Republic Plaza Tower I #26-01, Singapore 048619 |
| Auditors | BDO LLP |
| Other Stock Exchange Listings | *SINGAPORE EXCHANGE (CATALIST) |
| Background | iX Biopharma Ltd is a specialty pharmaceutical and nutraceutical company, operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. iX Biopharma focus on the development and commercialisation of therapies for diseases of the central nervous system using its novel, patent-protected platform sublingual drug delivery technology, WaferiX. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. Silcap is also approved in Singapore. iX Biopharma’s Xativa is the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited (Entity), is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through pharmacies and health food shops and in China and globally through its online e-commerce stores. |
| Last Updated | 05/27/2026 08:45:30 AM |
| Country | SINGAPORE |
© 2026 Dividends.sg